For example, the loss of EHF has been found to promote epithelial-mesenchymal transition and cell migration in conditions such as prostate cancer (18, 19), lung cancer (20, 21), pancreatic cancer, and esophageal squamous cell carcinoma. This evidence concerns the gene EHF and prostate carcinoma.